Elevara Medicines is a clinical-stage biotech company developing therapies for rheumatoid arthritis and chronic inflammatory diseases. The company's lead program, ELV001, is a first-in-class oral CDK4/6 inhibitor targeting fibroblast-like synoviocytes, aiming to disrupt early line RA treatment by achieving clinical remission in combination with standard care.
Leadership & Board
Current Number of Employees14
Current LinkedIn Followers1,241
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$70M
Total Amount Raised$70M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$70M
Latest Funding Amount$70M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Elevara Medicines had 14 employees as of September 28, 2026. The number of employees increased by 0 (0.00%) week-over-week.
14Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Elevara Medicines had 1,241 followers as of September 28, 2026. The number of followers increased by 2 (0.16%) week-over-week.
1,241Latest Followers Count
2(0.16%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.